Gavin  MacBeath net worth and biography

Gavin MacBeath Biography and Net Worth

Insider of TScan Therapeutics
Gavin MacBeath is the Chief Scientific Officer at TScan Therapeutics. He has two decades of experience in academia and industry, founding companies and driving research from early-stage discovery through drug approval. Prior to joining TScan, Gavin served as the Chief Scientific Officer at Abpro, where he advanced T cell-engaging bispecific antibodies through pre-clinical development. Previously, Dr. MacBeath served as Co-founder and SVP of Discovery at Merrimack Pharmaceuticals where he advanced several biologics through IND, Phase 1, and Phase 2 clinical development. Dr. MacBeath began his career in academia, where he served as the first fellow at Harvard’s Bauer Center for Genomics Research, as an Assistant Professor and later Associate Professor in the Department of Chemistry & Chemical Biology at Harvard University, and as Lecturer and Principal Investigator at Harvard Medical School. Dr. MacBeath received his undergraduate degree from the University of Manitoba, his Ph.D. from The Scripps Research Institute, and postdoctoral training with Dr. Stuart Schreiber at Harvard University.

When he’s away from running R&D at TScan, Gavin relaxes by running marathons and ultramarathons. Among his various races, he has completed 9 Boston Marathons, as well as the iconic Leadville LT100 race (a 100-mile trail race in the high Rocky Mountains of Colorado).

How old is Gavin MacBeath?

Mr. MacBeath is currently 54 years old. There are 1 older executives and no younger executives at TScan Therapeutics. The oldest executive at TScan Therapeutics is Mr. Jason A. Amello, Chief Financial Officer, who is 56 years old. Learn More on Gavin MacBeath's age.

How do I contact Gavin MacBeath?

The corporate mailing address for Mr. MacBeath and other TScan Therapeutics executives is 830 WINTER STREET, WALTHAM MA, 02451. TScan Therapeutics can also be reached via phone at 857-399-9500 and via email at [email protected]. Learn More on Gavin MacBeath's contact information.

Has Gavin MacBeath been buying or selling shares of TScan Therapeutics?

Gavin MacBeath has not been actively trading shares of TScan Therapeutics during the past quarter. Most recently, on Monday, September 20th, Gavin Macbeath bought 4,943 shares of TScan Therapeutics stock. The stock was acquired at an average cost of $6.22 per share, with a total value of $30,745.46. Learn More on Gavin MacBeath's trading history.

Who are TScan Therapeutics' active insiders?

TScan Therapeutics' insider roster includes Gavin MacBeath (Insider), Brian Silver (CFO), and Zoran Zdraveski (Insider). Learn More on TScan Therapeutics' active insiders.

Are insiders buying or selling shares of TScan Therapeutics?

In the last year, TScan Therapeutics insiders bought shares 3 times. They purchased a total of 71,710 shares worth more than $266,003.10. In the last year, insiders at the sold shares 1 times. They sold a total of 25,400 shares worth more than $64,008.00. The most recent insider tranaction occured on December, 18th when Director Timothy J Barberich bought 28,830 shares worth more than $140,978.70. Insiders at TScan Therapeutics own 8.3% of the company. Learn More about insider trades at TScan Therapeutics.

Information on this page was last updated on 12/18/2023.

Gavin MacBeath Insider Trading History at TScan Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2021Buy4,943$6.22$30,745.46View SEC Filing Icon  
See Full Table

Gavin MacBeath Buying and Selling Activity at TScan Therapeutics

This chart shows Gavin Macbeath's buying and selling at TScan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TScan Therapeutics Company Overview

TScan Therapeutics logo
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $7.29
Low: $7.04
High: $7.46

50 Day Range

MA: $7.17
Low: $6.45
High: $8.30

2 Week Range

Now: $7.29
Low: $1.62
High: $9.00

Volume

107,354 shs

Average Volume

185,302 shs

Market Capitalization

$349.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9